Concepedia

Adrian L. Gill

AL

35

Publications

2.7K

Citations

25

H-Index

2001

Active since

Affiliations

Revolution Medicines (United States)(Current)

Memorial Sloan Kettering Cancer Center

AstraZeneca (United Kingdom)

Harvard University

Cornell University

Adrian L. Gill is an author at Revolution Medicines (United States) specializing in medicine, pharmacology, and drug discovery.

Top concepts

MedicinePharmacologyDrug DiscoveryCell BiologyTumor BiologyCancer BiologyCancer ResearchRadiation OncologyCancer Cell BiologySystems Biology

Publications per year

2001–2025

35

Publications

35

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Robert J. Nichols, Franziska Haderk, Carlos Stahlhut et al. · Nature Cell Biology · 2018 · 407 citations · Full text

Ras-driven Cancers, Tumor Biology, Mutant Braf- +9

Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity

Steven Howard, Valério Berdini, John A. Boulstridge et al. · Journal of Medicinal Chemistry · 2008 · 329 citations · Full text

Drug Target, Pyrazol-4-yl Urea, Clinical Candidate +18

Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy

Matthew Holderfield, Bianca J. Lee, Jingjing Jiang et al. · Nature · 2024 · 268 citations · Full text

Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers

Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato et al. · Cancer Discovery · 2024 · 231 citations · Full text

Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS

Christopher J. Schulze, Kyle J. Seamon, Yulei Zhao et al. · Science · 2023 · 203 citations · Full text

Rows per page

1–5 of 35